Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a product name.
BioCentury | Mar 26, 2025
Product Development
Axsome’s latest win comes in ADHD, Opthea seeks path after AMD miss, and more: Clinical Report
Plus:
BioCentury | Mar 15, 2025
Data Byte
VEGF ophthalmic sales: Vabysmo gains ground, biosimilars struggle to take off
Eylea remains market leader as Roche’s grows its share of AMD pie; biosimilars still a rounding error
BioCentury | Dec 4, 2024
Product Development
Confidence in masked T cell engagers builds with Janux update
Also in BioCentury’s Clinical Report: Cartesian’s autoimmune CAR T durability, Roivant’s miss, Novocure’s pancreatic cancer data, and more
BioCentury | Nov 8, 2024
Deals
With Eylea rival in clinic, once-stealthy Kalaris finds public path via merger
Samsara-backed start-up launched by former Genentech colleagues picks AlloVir as vehicle to reach NASDAQ
BioCentury | Sep 1, 2023
Finance
The Platform Powerhouse: Regeneron
Back to School 2023 case study: Regeneron’s is a story of leveraging platform technology to repeatedly generate high-value assets
BioCentury | Sep 8, 2022
Product Development
Regeneron aims to extend Eylea franchise as high-dose aflibercept hits in Phase III
Commercial success will depend on physician willingness to switch to high-dose aflibercept in increasingly competitive market
BioCentury | Aug 19, 2022
Finance
Carlyle, Abingworth back Opthea’s AMD ambitions in largest-ever Australian deal
First risk-sharing investment since VC’s takeout will position strategic entity Launch to advise Australian biotech as it navigates Phase III with up to $260M
BioCentury | Aug 3, 2022
Finance
Aug. 2 Quick Takes: Yescarta label expansion buoys Gilead’s 2Q22 sales
Plus Megaround for Sironax, and updates from Eleven, Roche, Axcella, Phathom, and more
BioCentury | Jun 3, 2022
Deals
June 2 Quick Takes: BMS, Immatics expand partnership to allogeneic T cells
Plus Transition’s $50M A round, Centessa’s killed kidney program and updates from Centessa, Aeglea, Immunic and more
BioCentury | Apr 4, 2022
Product Development
Novartis’ new page prioritizes ‘high-value’ multibillion dollar assets
Narasimhan’s restructuring reunites oncology with rest of pharma, creates new role of chief strategy & growth officer
Items per page:
1 - 10 of 678